Form 4: Fulgent Genetics CFO Paul Kim Boosts Stake

Fulgent Genetics CFO and Treasurer Paul Kim reported an increase in his beneficial ownership of common stock following multiple restricted stock unit vestings and associated tax withholdings.

Summary

• Paul Kim, CFO and Treasurer of Fulgent Genetics, Inc. (FLGT), reported multiple transactions involving the company's common stock.
• On February 23, 2026, 661 shares were withheld at $23.01 to satisfy tax obligations related to restricted stock units (RSUs) granted on February 23, 2023.
• On February 24, 2026, Kim acquired a total of 47,320 shares through the vesting of performance-based RSUs granted on February 23, 2023 (5,721 shares), February 26, 2024 (14,926 shares), and February 25, 2025 (26,673 shares), all at a price of $0.
• Also on February 24, 2026, a total of 26,792 shares were withheld at $23.09 to cover tax obligations arising from the vesting of these performance-based RSUs.
• Additionally, on February 24, 2026, Kim acquired 31,182 restricted stock units at $0, which will vest over a period of three years, with the first third vesting 12 months after March 1, 2026, and subsequent vesting quarterly.
• Following these transactions, Kim's direct beneficial ownership increased by a net of 51,049 shares, reaching a total of 379,195 shares of common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal. While tax withholdings are a neutral event, the significant net increase in the CFO's beneficial ownership through RSU vesting, including performance-based awards, suggests management confidence and achievement of internal targets.

Positives

• Paul Kim's beneficial ownership of Fulgent Genetics common stock increased by 51,049 shares, demonstrating continued alignment with shareholder interests.
• The vesting of 47,320 performance-based restricted stock units indicates the achievement of certain performance milestones by the company.
• The grant of an additional 31,182 restricted stock units reinforces management's long-term commitment to the company, with vesting tied to continued service.

Negatives

• A total of 27,453 shares were disposed of to satisfy tax withholding obligations, which is a reduction in direct beneficial ownership, albeit a standard practice for RSU vesting.

Future Outlook

The filing indicates a future vesting schedule for 31,182 restricted stock units, with the first tranche vesting 12 months after March 1, 2026, and subsequent vesting quarterly over the following 24 months, contingent on continued service.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as the vesting of restricted stock units and subsequent tax withholdings, are common compensation practices in the biotechnology and diagnostics industry. While these transactions reflect compensation events rather than discretionary open-market purchases, the increase in beneficial ownership for a key executive like the CFO can be viewed as a positive signal of continued alignment with the company's long-term performance.

Stakeholder Impact

• Shareholders: The increase in the CFO's beneficial ownership aligns his interests more closely with shareholders, potentially signaling confidence in future performance.
• Employees: The vesting of performance-based RSUs can serve as a positive example of compensation tied to company performance.

Next Steps

• Vesting of 1/3rd of 31,182 restricted stock units 12 months after March 1, 2026.
• Subsequent vesting of 1/12th of the remaining 31,182 restricted stock units at the end of every three-month period thereafter over the remaining 24 months.

Key Dates

Recommendation

The filing details routine insider transactions related to executive compensation, specifically the vesting of restricted stock units and associated tax withholdings. While the net increase in beneficial ownership is a positive signal of management alignment, these are not discretionary open-market purchases or sales that would typically warrant a change in investment recommendation. The information is largely expected and does not present new fundamental data to alter a seasoned investor's stance.

Keywords

Fulgent Genetics, FLGT, Paul Kim, CFO, insider transaction, Form 4, restricted stock units, RSU vesting, stock ownership, performance-based compensation, tax withholding